<DOC>
	<DOCNO>NCT01563497</DOCNO>
	<brief_summary>The primary purpose study estimate relative bioavailability food effect PF-05089771 tablet .</brief_summary>
	<brief_title>A Study Comparing PF-05089771 TS Tablet PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or nonchildbearing potential female subject age 18 55 year Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Treatment investigational drug within 60 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . Screening supine blood pressure ≥140 mm Hg ( systolic ) ≥90 mm Hg ( diastolic ) , single measurement ( confirm single repeat , necessary ) follow least 5 minute rest 7 . Single 12lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 mseca screening . If QTc exceed 450 msec , QRS exceed &gt; 120 mseca ECG repeat two time average three QTc QRS value use determine subject 's eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>